Intravenous ziprasidone for treatment of delirium in the intensive care unit

Anesthesiology

Volumn 101, Issue 3, 2004, Pages 794-795

  Young, Christopher C ^a,b   Lujan, Eugenio ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CISATRACURIUM; CLONAZEPAM; CLONIDINE; DEXMEDETOMIDINE; FENTANYL; HALOPERIDOL; HYDROMORPHONE; LORAZEPAM; METHADONE; MIRTAZAPINE; PROPOFOL; RISPERIDONE; ZIPRASIDONE;

ADULT; AGITATION; ANXIETY DISORDER; ARTICLE; CASE REPORT; DELIRIUM; DEPRESSION; DISEASE SEVERITY; DRUG INDICATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERTENSION; INTENSIVE CARE UNIT; LENGTH OF STAY; MALE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PSYCHOTHERAPY; QT INTERVAL; SEDATION;

EID: 4344630011     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200409000-00031     Document Type: Article

References (15)

1. Brook S, Lucey JV, Gunn KP: Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psych 2000; 61:933-41
2. Ely EW, Inouye SK, Bernard GR, Gordon S, Francis J, May L, Truman B, Speroff T, Gautam S, Margolin R, Hart RP, Dittus R: Delirium in mechanically ventilated patients: Validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA 2001; 286:2703-10
3. Ely EW, Gautam S, Margolin R, Francis J, May L, Speroff T, Truman B, Dittus R, Bernard R, Inouye SK: The impact of delirium in the intensive care unit on hospital length of stay. Intensive Care Med 2001; 27:1892-900
4. McCusker J, Cole M, Abrahamowicz M, Han L, Podoba JE, Ramman-Haddad L: Environmental risk factors for delirium in hospitalized older people. J Am Geriatr Soc 2001; 49:1327-34
5. Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, Chalfin DB, Masica MF, Bjerke HS, Coplin WM, Crippen DW, Fuchs BD, Kelleher RM, Marik PE, Nasraway SA Jr., Murray MJ, Peruzzi WT, Lumb PD, Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists (ASHP), American College of Chest Physicians: Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002; 30:119-41
6. Riker RR, Fraser GL Cox PM: Continuous infusion of haloperidol controls agitation in critically ill patients. Crit Care Med 1994; 22:433-40
7. Metzger E, Friedman R: Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psychopharmacol 1993; 13:128-32
8. Wilt JL, Minnema AM, Johnson RF, Rosenblum AM: Torsades de pointes associated with the use of intravenous haloperidol. Ann Intern Med 1993; 119:391-4
9. Sharma ND, Rosman HS, Padhi D, Tisdale JE: Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998; 81:238-40
10. Glassman AH, Bigger JT: Anti-psychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158:1774-82
11. Psychopharmacological Drugs Advisory Committee: Briefing document for Zeldox capsules (Ziprasidone HCl). Rockville, MD: Food and Drug Administration of the United States Department of Health and Human Services; July 19, 2000. NDA-825: 1-173
12. Pfizer Pharmaceuticals, Inc. Geodon [package insert]. NewYork, NY: Pfizer, 2002
13. Caley CF, Cooper CK: Ziprasidone: The fifth atypical antipsychotic. Ann Pharmacother 2002; 36:839-51
14. Schwanz TL, Masand PS: The role of atypical antipsychotics in the treatment of delirium. Psychosomatics 2002; 43:171-4
15. Leso L, Schwartz TL: Ziprasidone treatment of delirium. Psychosomatics 2002; 43:61-2